Allitol is a sugar alcohol derived from allose, a rare aldohexose. It is a white crystalline solid that is soluble in water. Allitol has been shown to have a number of interesting biological properties, including anti-inflammatory and antioxidant effects. It has also been shown to be effective in reducing blood sugar levels in diabetic animals. Allitol is currently being studied as a potential treatment for a variety of diseases, including diabetes, cancer, and inflammatory diseases.'
allitol: structure in first source
ID Source | ID |
---|---|
PubMed CID | 120700 |
CHEBI ID | 181263 |
SCHEMBL ID | 15545455 |
MeSH ID | M0520063 |
Synonym |
---|
(2r,3r,4s,5s)-hexane-1,2,3,4,5,6-hexol |
CHEBI:181263 |
488-44-8 |
allitol |
d-allitol |
A832929 |
(2r,3r,4s,5s)-hexane-1,2,3,4,5,6-hexol;dulcitol |
b3f996o6ju , |
unii-b3f996o6ju |
AKOS006323056 |
S9347 |
allodulcit |
allodulcitol |
x9x , |
mfcd11519461 |
FBPFZTCFMRRESA-FBXFSONDSA-N |
SCHEMBL15545455 |
W-202859 |
wurcs=2.0/1,1,0/[h2222h]/1/ |
allitol, >=98% |
DTXSID60197607 |
allit |
Q27467495 |
HY-N2840 |
l-allitol |
CCG-266440 |
dulcitol; melampyrit; nsc 1944 |
CS-0023414 |
D88490 |
Allitol is a hexitol produced by reducing the rare sugar D-allulose with a metal catalyst under hydrogen gas. It is a kind of rare sugar alcohol with potential application value.
Excerpt | Reference | Relevance |
---|---|---|
"Allitol is a rare sugar alcohol obtained by reducing d-allulose (d-psicose). " | ( Effects of Dietary Allitol on Body Fat Accumulation in Rats. Higaki, S; Inai, R; Matsuo, T, 2022) | 2.49 |
"Allitol is a hexitol produced by reducing the rare sugar D-allulose with a metal catalyst under hydrogen gas. " | ( Safety evaluation and maximum use level for transient ingestion in humans of allitol. Akimitsu, K; Inazu, T; Izumori, K; Kato, S; Kimura, I; Kishimoto, Y; Matsuo, T; Miyoshi, M; Mochizuki, S; Yoshida, H; Yoshihara, A, 2023) | 2.58 |
"Allitol is a kind of rare sugar alcohol with potential application value. " | ( Efficient Allitol Bioproduction from D-Fructose Catalyzed by Recombinant E. coli Whole Cells, and the Condition Optimization, Product Purification. Li, C; Lin, H; Lin, J; Ren, Y; Song, X; Wen, X; Zhang, C, 2020) | 2.4 |
Excerpt | Reference | Relevance |
---|---|---|
" To confirm the safe level of allitol, we conducted a series of safety assessments." | ( Safety evaluation and maximum use level for transient ingestion in humans of allitol. Akimitsu, K; Inazu, T; Izumori, K; Kato, S; Kimura, I; Kishimoto, Y; Matsuo, T; Miyoshi, M; Mochizuki, S; Yoshida, H; Yoshihara, A, 2023) | 1.43 |
Class | Description |
---|---|
hexitol | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (23.08) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 8 (61.54) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.82) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |